RIGVIR® is the first oncolytic virus in the world, which is registered for cancer virotherapy and introduced in medical practice. RIGVIR® was approved in Latvia in 2004 for cutaneous melanoma therapy. Task – create illustrations, booklets, packaging label design and different print designs.
Rigvir
